Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | CNR1 | P21554 | 15/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426317 | 1.00 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL29835924 | 1.00 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL29448220 | 1.00 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL9089051 | 0.93 | CNR2 (0.87) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL8932661 | 0.92 | CNR2 (1.00) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL14201282 | 0.91 | CNR2 (0.84) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL10068292 | 0.91 | CNR2 (0.85) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL2833584 | 0.89 | CNR2 (0.85) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL15995557 | 0.87 | CNR2 (0.82) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL9089488 | 0.87 | CNR2 (0.78) | CNR2CNR1TP53CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| US-9289421-B2 | Methods and compositions for reducing serum levels of immunoglobulin E (IgE) | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-22 | — | — | US | claimed |
| US-20140350052-A1 | Methods and Compositions for Reducing Serum Levels of Immunoglobulin E (IGE) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | claimed |
| US-20140142106-A1 | METHOD FOR TREATING PERITONEAL FIBROSIS | TAIPEI VETERANS GENERAL HOSPITAL (TW) | 2014-05-22 | — | — | US | claimed |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-26 | — | — | US | claimed |
| WO-2006111424-A1 | METHODS FOR IDENTIFYING MODULATORS OF CB1 AND CB2 CANNABINOID RECEPTORS AND THEIR USE IN WOUND HEALING | LIFE & BRAIN GMBH (DE) | 2006-10-26 | — | — | WO | claimed |
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | CELLA THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-116640118-A | Radiolabeled cannabinoid receptor 2 ligands | 豪夫迈·罗氏有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | WYLDER NATION FOUNDATION | 2023-06-15 | — | — | US | disclosed |
| CN-112638430-B | Radiolabeled cannabinoid receptor 2 ligands | 豪夫迈·罗氏有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4153169-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | Wylder Nation Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |
| EP-1453497-A1 | USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | AstraZeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003043619-A1 | NEW USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2003-05-30 | — | — | WO | disclosed |
| WO-1996025397-A1 | INDOLE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID RECEPTOR | MERCK FROSST CANADA INC. (CA) | 1996-08-22 | — | — | WO | disclosed |
| US-5532237-A | INTRAOCULAR FOR TREATMENT OF GLAUCOMA | MERCK FROSST CANADA, INC. (CA) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131008-A1 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | SLC26A6, SLC26A3, SLC9A2 | CNR2 1399/4885CNR1 1606/4885TP53 3337/4885 |
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | ADA, SLC29A1, SLC29A2 | CNR2 4580/4885CNR1 4154/4885TP53 2165/4885 |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | GBA1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885TP53 3307/4885 |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TP53 4735/4885 |
| US-20120022063-A1 | Oligomer-Cannabinoid Conjugates | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TP53 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.